Ocean Biomedical, Inc. (NASDAQ: OCEA) is a preclinical biotech company focused on moving new therapeutic candidates efficiently from the laboratory to the
Ocean Biomedical (NASDAQ: OCEA) Research Summary
Categories
Biotechnology
Trxade Health (MEDS) Q2 2024 Research Summary
Trxade Health, Inc. (NASDAQ: MEDS) is a drug procurement and delivery platform with a mission to revolutionize the healthcare industry by offering
MEDS Earnings: A snapshot of Trxade’s Q2 2024 results
Health services IT company Trxade Health, Inc. (NASDAQ: MEDS) announced financial results for the second quarter of 2024, reporting a narrower net
Earnings Summary: Gilead Sciences reports higher Q2 revenue and profit
Gilead Sciences, Inc. (NASDAQ: GILD), a leading research-based biopharmaceutical company, has reported an increase in revenues and adjusted earnings for the second
LLY Earnings: Highlights of Eli Lilly’s Q2 2024 financial report
Eli Lilly and Company (NYSE: LLY) on Thursday reported a double-digit increase in revenues and profit for the second quarter of 2024.
Earnings Summary: Moderna reports Q2 2024 financial results
Biotechnology company Moderna, Inc. (NASDAQ: MRNA) Thursday reported a sharp decline in revenues for the second quarter of 2024. Second-quarter revenues decreased
Merck (MRK) swings to profit in Q2 on higher revenues; earnings beat
Pharmaceutical company Merck & Co. Inc. (NYSE: MRK) reported net profit for the second quarter of 2024, on an adjusted basis, compared
BMY Earnings: Bristol-Myers Squibb reports higher Q2 revenue and profit
Biotechnology company Bristol Myers Squibb (NYSE: BMY) Friday reported higher revenues and net profit for the second quarter of 2024. Net income
Everything you need to know about OS Therapies’ upcoming IPO
There has been a strong uptick in IPO activity this year compared to 2023 when the market witnessed a slowdown. In the
Alumis looks to raise $300 million in IPO. Here’s what you need to know
Technology and healthcare companies are continuing to dominate the IPO market, which is witnessing a significant increase in activity compared to 2023.
Ocean Biomedical (NASDAQ: OCEA) Research Summary
Ocean Biomedical, Inc. (NASDAQ: OCEA) is a new-generation biotechnology firm that works to accelerate the development of new therapies by partnering with
Cigna Group (CI) reports double-digit revenue growth for Q1; guides FY24
The Cigna Group (NYSE: CI), a healthcare company focused on medical insurance and related services, Thursday reported a sharp increase in revenues for
Infographic: A snapshot of Moderna’s (MRNA) Q1 2024 earnings results
Moderna, Inc. (NASDAQ: MRNA) reported a net loss for the first quarter of 2024 when the biotechnology company's revenues declined sharply. Q1
MRK Earnings: Merck Q1 2024 profit jumps on 9% revenue growth
Pharmaceutical company Merck & Co. Inc. (NYSE: MRK) reported a sharp increase in adjusted earnings for the first quarter of 2024, aided
BIIB Earnings: Biogen Q1 2024 adj. earnings rise despite lower revenues
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) Wednesday reported an increase in adjusted profit for the first quarter of 2024, despite a decline
Key highlights from Abbott Laboratories (ABT) Q1 2024 earnings results
Abbott Laboratories (NYSE: ABT) reported its first quarter 2024 earnings results today. Total sales increased 2.2% year-over-year to $10 billion. Organic sales growth
Femasys is committed to providing women with revolutionary healthcare products: CEO
Femasys Inc. (NASDAQ: FEMY) is a healthcare company that develops women's reproductive health solutions using state-of-the-art technology. The company’s portfolio includes minimally
IPO Alert: What to look for when Boundless Bio goes public
Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of
Infographic: Highlights of Moderna’s (MRNA) Q4 2023 earnings results
Biotechnology company Moderna, Inc. (NASDAQ: MRNA) reported a sharp decline in revenues and earnings for the fourth quarter of 2023. Net income
Ocean Biomedical, Inc. (NASDAQ: OCEA) Research Summary
Ocean Biomedical, Inc. (NASDAQ: OCEA) is a biotechnology company that works with leading researchers and institutions to accelerate the development of new
BIIB Earnings: Here’s everything you need to know about Biogen’s Q4 report
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) reported lower earnings, on an adjusted basis, and revenues for the fourth quarter of 2023. Total